- Home
- RNXT
RNXT
RenovoRx Inc.
as 07-26-2024 4:00pm EST
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SAN JOSE |
| Market Cap: | 27.1M | IPO Year: | 2021 |
| Target Price: | $6.00 | AVG Volume (30 days): | 25.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.72 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.53 - $2.35 | Next Earning Date: | 08-15-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest RenovoRx Inc. News
RNXT Breaking Stock News: Dive into RNXT Ticker-Specific Updates for Smart Investing
GlobeNewswire
19 days ago
RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist®
GlobeNewswire
a month ago
University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx’s Pivotal Phase III TIGeR-PaC Clinical Trial
GlobeNewswire
2 months ago
RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships
Business Wire
2 months ago
RenovoRx CEO Issues Update Letter to Shareholders
Business Wire
2 months ago
Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx’s TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment Delivery
Business Wire
2 months ago
RenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024
Business Wire
3 months ago
RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024
Business Wire
3 months ago
RenovoRx Regains Compliance with Nasdaq Stockholders’ Equity Requirement
Compare RNXT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RNXT RenovoRx Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.